Additionally, rad53 complementation assays using the DNA damaging agent, methyl methanesulfonate (MMS) have been performed to evaluate the functional impact of over 100 germline missense variants detected in familial breast cancer patients or selected from the ClinVar database [33–35]. Here, CHEK2 is linked to breast carcinoma.